A Phase I Open Label Study of GSK3359609 Administered alone in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Locally/metastatic Advanced Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have histological or cytological documentation of bladder cancer, cervical cancer, colorectal cancer, esophageal cancer with squamous cell, head and neck cancer, melanoma, malignant pleural mesothelioma (MPM), non-small cell lung cancer (NSCLC), or prostate cancer


    2.  Patients must have a life expectancy of at least 12 weeks

You may not be eligible for this study if the following are true:

  • 1.  Patients who received more than 5 prior lines of therapy for advanced disease including both standards of care and investigational therapies.

    2.  Patients with prior treatment of the following therapies:  Anticancer therapy within 30 days; prior radiation therapy; or investigational therapy within 30 days.


    3.  Prior allogeneic or autologous bone marrow transplantation or other solid organ transplantation

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.